IDH1 and glioblastoma: We observed augmented inhibition of tumour growth (Fig. 7b,f,g and Extended Data Fig. 10g) and improved survival (Fig. 7c,h) when TMZ treatment was combined with DHX inhibitor in patient-derived IDH-wild-type glioblastoma cells (the combinational index was below one, Extended Data Fig. 10h).